ABS — Arctic Bioscience AS Income Statement
0.000.00%
Last trade - 00:00- NOK78.90m
- NOK86.28m
- NOK43.48m
- 15
- 47
- 38
- 21
Annual income statement for Arctic Bioscience AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | NAS | NAS | NAS | NAS | NAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 20.5 | 21.5 | 34.3 | 33.8 | 43.5 |
| Cost of Revenue | |||||
| Gross Profit | 5.31 | 5.16 | 11.6 | 9.77 | 11.9 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 42.2 | 62.1 | 71.7 | 82.3 | 91.3 |
| Operating Profit | -21.7 | -40.6 | -37.4 | -48.6 | -47.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.6 | -42.6 | -34 | -45.5 | -47.9 |
| Net Income After Taxes | -22.6 | -42.6 | -34 | -45.5 | -47.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.6 | -42.6 | -34 | -45.5 | -47.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.6 | -42.6 | -34 | -45.5 | -47.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.89 | -1.67 | -1.28 | -1.78 | -1.87 |
| Dividends per Share |